Exelixis
Jeremy Murray has over two decades of experience in the pharmaceutical industry. Jeremy started their career at Chiron/Novartis in 2002 as a Scientist/Principal Scientist. Jeremy then moved to Novartis NIBR in 2006 as a Research Investigator II. In 2008, Jeremy joined Genentech where they held various roles, including Scientist & Group Leader and Senior Scientist & Group Leader, until 2022. Currently, they are working at Exelixis as a Sr Principal Scientist & Group Leader.
Jeremy Murray has a PhD in Biochemistry and Structural Molecular Biology from the University of Leeds. Jeremy completed their post-doctoral research in Biophysics & Biochemistry at Yale University from 1999 to 2022. Additionally, they attended the University of California, Berkeley for Project Management, but no specific dates were provided.
Exelixis
15 followers
Exelixis strives to deliver results and new medicines to treat and defeat cancer, giving patients hope for the future.